Welcome to our dedicated page for Pmv Pharmaceuticals SEC filings (Ticker: PMVP), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Decoding a clinical-stage biotech is hard. PMV Pharmaceuticals’ SEC filings weave together p53 science, cash-burn math, and milestone disclosures that span hundreds of pages. If you’ve ever asked, “How do I find PMV Pharmaceuticals’ quarterly earnings report 10-Q filing?” or needed “PMV Pharmaceuticals insider trading Form 4 transactions” before the market reacts, you know the challenge.
Stock Titan solves it. Our AI-powered summaries turn dense 10-Ks into clear takeaways—R&D spend, cash runway, and risk factors—so “PMV Pharmaceuticals annual report 10-K simplified” is more than a promise. Real-time EDGAR feeds push “PMV Pharmaceuticals Form 4 insider transactions real-time” to your dashboard within seconds, letting you monitor executive stock moves the moment they’re filed. Need context on a sudden press release? Click the linked 8-K; our engine delivers “PMV Pharmaceuticals 8-K material events explained” with plain-English highlights.
Every filing type is covered: 10-Q earnings reports for trial-funding updates, 8-K notices for dose-escalation data, Schedule 13G for institutional positions, and the proxy statement for “PMV Pharmaceuticals proxy statement executive compensation” details. Use cases include comparing quarter-over-quarter burn, tracking pipeline progress through clinical milestones, and spotting “PMV Pharmaceuticals executive stock transactions Form 4” that precede key readouts. Whether you search for “understanding PMV Pharmaceuticals SEC documents with AI” or “PMV Pharmaceuticals earnings report filing analysis,” Stock Titan delivers concise answers, real-time alerts, and downloadable originals—so you spend time analyzing opportunities, not hunting for documents.
PMV Pharmaceuticals (PMVP) — Form 4 insider transaction: An affiliated holder reported a sale of 1,000,000 shares of Common Stock on 10/23/2025 at a price of $1.52 per share. Following the transaction, 4,975,291 shares were reported as beneficially owned indirectly.
According to the footnotes, the shares are held by OrbiMed Private Investments V, LP, with OrbiMed Capital GP V LLC as general partner and OrbiMed Advisors LLC as managing member. The filing notes that the reporting persons may be deemed to share voting and investment power through these relationships and include customary disclaimers of beneficial ownership beyond pecuniary interest. The reporting relationship is indicated as Director and 10% Owner.
Tang Capital group reports collective ownership of 4,720,357 shares of PMV Pharmaceuticals common stock, representing 8.9% of the outstanding class. The filing discloses that Tang Capital Management, LLC, Kevin Tang, Tang Capital Partners, LP and Tang Capital Partners International, LP share voting and dispositive power over these shares. The ownership figures are based on 52,990,864 shares outstanding as of August 6, 2025, per the issuer's quarterly report.
The statement clarifies that the reported securities were not acquired to change or influence control of PMV and lists office addresses and organizational domiciles for the reporting entities and individuals.
PMV Pharmaceuticals, Inc. (PMVP) filed a Form 144 notice reporting a proposed sale of 2,283,654 shares of Common Stock through broker Themis Trading LLC with an approximate aggregate market value of $3,653,846.40. The filing lists the number of shares outstanding as 52,990,864 and gives an approximate sale date of 09/10/2025 on NASDAQ.
The securities were acquired on 09/29/2020 in the issuer's Initial Public Offering with cash payment. The filer certifies there were no securities sold in the past three months by the person for whose account the securities will be sold and represents they are unaware of any material nonpublic information about the issuer.
PMV Pharmaceuticals, Inc. (PMVP) filed an 8-K reporting a material event: the company issued a press release and hosted an investor webinar on September 10, 2025 to present interim monotherapy data for rezatapopt from the PYNNACLE Phase 2 trial in multiple solid tumors with a TP53 Y220C mutation. The press release is attached as Exhibit 99.2 and is incorporated by reference into the filing.
The filing notes the public dissemination of clinical interim results and the webinar but does not include the data tables or numerical results within the 8-K text itself. No financial results, enrollment counts, regulatory actions, or next-step timelines are disclosed in the provided excerpt.
PMV Pharmaceuticals (PMVP) reports that Sio Capital Management, LLC beneficially owns 3,735,396 shares of common stock, equal to 7.19% of the class. The filing states Sio has shared voting and shared dispositive power over these shares and reports no sole voting or dispositive power, reflecting an adviser-managed position held for client funds.
The percentage is calculated using 51,952,680 shares outstanding as reported by the issuer. The filing notes Sio acts as investment adviser to affiliated funds that are the record owners and discloses that Sio GP, LLC and Michael Castor may be viewed as having influence, although any such beneficial ownership is expressly disclaimed. The statement also certifies the securities are held in the ordinary course of business and not to change or influence control.
PMV Pharmaceuticals, Inc. (PMVP) filed a Form 4 disclosing that General Counsel & COO Robert Ticktin sold 23,151 common shares on 1 July 2025 at an average price of $1.0648 per share.
The filing states the shares were withheld for tax obligations arising from the vesting of restricted stock units (RSUs). Following the transaction, Ticktin retains 98,695 shares of PMVP, which include 15,528 shares purchased under the company’s Employee Stock Purchase Plan on 15 May 2025. No derivative security transactions were reported.
The sale represents a disposition of approximately 19% of his prior directly held shares; however, because the purpose is tax-related rather than discretionary, the market signal is typically viewed as neutral.
PMV Pharmaceuticals (PMVP) – Form 4 insider transaction
Chief Financial Officer Michael Carulli disclosed the sale of 28,249 common shares on 01 July 2025 at a weighted-average price of $1.0647 per share. According to the filing, the disposition was made solely to satisfy tax-withholding obligations triggered by the vesting of restricted stock units (RSUs). After the transaction, the executive continues to beneficially own 60,146 shares of PMVP common stock, and no derivative security activity was reported. The sale represents a cash value of roughly $30,000 and leaves the CFO with a meaningful equity stake, limiting the signaling impact for investors.
FAQ
What is the current stock price of Pmv Pharmaceuticals (PMVP)?
What is the market cap of Pmv Pharmaceuticals (PMVP)?
